SeaStar Medical Reports Strong Q1 Growth, Sets Sights on Expanding Adult Acute Kidney Injury Market
TL;DR
SeaStar Medical's QUELIMMUNE sales saw a fourfold increase, driving revenue growth and potential market dominance in critical care treatments.
QUELIMMUNE, SeaStar Medical's FDA-approved product, connects to existing hemodialysis systems, offering organ-sparing and cost-effective treatment for pediatric AKI patients.
SeaStar Medical's innovative therapies aim to save lives by providing potential life-saving treatments for critically ill pediatric patients, with plans to expand to adult AKI market.
SeaStar Medical's rapid revenue growth and expansion plans in critical care treatments showcase a promising future for patients and healthcare advancements.
Found this article helpful?
Share it with your network and spread the knowledge!
SeaStar Medical demonstrated strong sequential growth in the first quarter of 2025, with QUELIMMUNE sales increasing fourfold to $293,000 and the company positioning itself to enter the expansive adult acute kidney injury (AKI) market.
The company's breakthrough product, QUELIMMUNE, is currently FDA-approved for pediatric patients with life-threatening AKI due to sepsis. While the pediatric market represents approximately 4,000 patients annually, SeaStar is targeting the substantially larger adult AKI market, estimated at $4.5 billion annually.
The company's NEUTRALIZE-AKI pivotal trial, evaluating its Selective Cytopheretic Device (SCD) therapy in adult patients, has reached 50% enrollment. If successful, SeaStar anticipates filing for adult AKI market approval in 2026, potentially transforming treatment options for critically ill patients.
Beyond sales growth, SeaStar reported narrowing its net loss to $3.8 million in the first quarter and ending the period with $5.3 million in cash. The company has also received two additional Breakthrough Device Designations, bringing its total to six therapeutic indications.
CEO Eric Schlorff emphasized the company's commitment to improving patient outcomes, noting that QUELIMMUNE offers organ-sparing and potentially life-saving treatment for critically ill pediatric patients. The company is now focused on expanding its customer base and preparing for potential adult market entry.
Curated from NewMediaWire
